TOXODIAG aims to evaluate the ELISPOT (Enzyme-Linked Immunosorbent SPOT assay) method for detecting in newborns B lymphocytes (LyB) sensitized in utero to produce immunoglobulins (Ig) specific for Toxoplasma gondii following a primary infection of the mother during pregnancy. The detection and quantification by the ELISPOT method of LyB secreting IgG and IgM specific for T. gondii will be applied i) to mononuclear cells of women in seroconversion following a primary toxoplasma infection during pregnancy and ii) to mononuclear cells cord blood from neonates suspected of congenital toxoplasmosis, compared to positive and negative infection controls.
The TOXODIAG study is carried out in the maternity wards of five AP-HP hospitals (Armand Trousseau, Bichat, Cochin, Jean Verdier and Louis Mourier), with inclusions in progress until the end of 2022. (https://clinicaltrials.gov /ct2/show/NCT03385499)
Northern Partnership
- Maternities AP-HP Armand Trousseau,
- Bichat, Cochin,
- John Verdier,
- Louis Mourier,
Southern Partnership
Calendar
2017 – 2023
